BC
CYTK icon

Brookfield Corp’s Cytokinetics CYTK Stock Holding History

Brookfield Corp’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-77,642
Closed -$3.56M – 686
2022
Q4 		$3.56M Sell
77,642
-22,224
-22% -$956K 0.01% 320
2022
Q3 		$4.84M Buy
99,866
+49,995
+100% +$2.41M 0.02% 284
2022
Q2 		$1.96M Buy
+49,871
New +$2.01M 0.01% 415

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Brookfield Corp's CYTK Position: Q1 2023 in Review

Brookfield Corp sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 77,642 shares — an estimated $3.56M sold.

Brookfield Corp first reported a position in CYTK in Q2 2022 and held it in 3 quarters. The position peaked at $4.84M in Q3 2022. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

  • Brookfield Corp reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
  • Brookfield Corp sold 77,642 Cytokinetics shares in Q1 2023, an estimated $3.56M.
  • Brookfield Corp first reported a position in Cytokinetics in Q2 2022 and held it in 3 quarters.
  • Brookfield Corp's Cytokinetics position peaked at $4.84M in Q3 2022.
  • 262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.